News headlines about Allena Pharmaceuticals (NASDAQ:ALNA) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allena Pharmaceuticals earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 50.9308090622929 out of 100, indicating that recent media coverage is somewhat likely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern’s rankings:
- Brokerages Expect Allena Pharmaceuticals (ALNA) to Post -$0.39 Earnings Per Share (americanbankingnews.com)
- Analysts’ Top Healthcare Picks: EIGR, MGEN (analystratings.com)
- Allena Pharmaceuticals, Inc. (ALNA) Reaches $16.17 After 3.00% Down Move; Altalis Capital Management Has … (mtastar.com)
- Investors Burrowing into Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA)’s Returns (derbynewsjournal.com)
- Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA) Quant Score & ROE in Focus (parkcitycaller.com)
Shares of Allena Pharmaceuticals opened at $16.00 on Friday, MarketBeat.com reports. The firm has a market cap of $334.65 million and a PE ratio of -3.33. The company has a current ratio of 12.06, a quick ratio of 12.06 and a debt-to-equity ratio of 0.06. Allena Pharmaceuticals has a 52 week low of $16.40 and a 52 week high of $16.40.
A number of analysts have weighed in on ALNA shares. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Allena Pharmaceuticals in a research note on Wednesday, March 28th. Zacks Investment Research cut shares of Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, February 13th. Credit Suisse Group decreased their target price on shares of Allena Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 28th. B. Riley started coverage on shares of Allena Pharmaceuticals in a research note on Wednesday, April 25th. They set a “buy” rating and a $23.50 target price on the stock. Finally, Roth Capital started coverage on shares of Allena Pharmaceuticals in a research note on Monday, April 2nd. They set a “buy” rating and a $61.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $32.90.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.